-
In a first, HMC uses nuclear medicine to treat prostate cancer
28 Apr 2024 10:01 GMT
… tumors and those battling prostate cancer."
Dr. Maryam … with metastatic prostate cancer who have not responded to hormonal therapy.
Dr … neuroendocrine tumors and prostate cancer who have not … . Two patients with prostate cancer have been registered since …
-
Astellas’ XTANDI (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
25 Apr 2024 19:27 GMT
… the first and only novel hormone therapy available for the treatment … living with advanced prostate cancer. Many men with hormone-sensitive prostate cancer undergo arduous … Use in Additional Recurrent Early Prostate Cancer Treatment Setting [Press release]. …
-
Astellas announces EC approval of Xtandi for expanded prostate cancer use
25 Apr 2024 11:38 GMT
… non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are unsuitable … resistant prostate cancer and metastatic hormone-sensitive prostate cancer, the first hormone therapy … who have undergone definitive prostate cancer treatment will experience …
-
Treatment Patterns and Clinical Outcomes Among Patients With Metastatic Prostate Cancer Harboring Homologous Recombination Repair Mutations.
25 Apr 2024 07:49 GMT
… patients with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair … ), and ATM (21.0%). Novel hormonal therapy and taxane chemotherapy were most …
-
EC approves Astellas’ Xtandi for high-risk prostate cancer treatment
24 Apr 2024 11:23 GMT
… non-metastatic hormone-sensitive prostate cancer (nmHSPC) who are … first and only novel hormone therapy for this patient … early, recurrent hormone-sensitive prostate cancer setting. Astellas is … -metastatic castration-sensitive prostate cancer with BCR at …
-
Astellas' XTANDI™ (Enzalutamide) Granted European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting
24 Apr 2024 02:54 GMT
… the first and only novel hormone therapy available for the treatment of … -sensitive prostate cancer (mHSPC), metastatic castration-resistant prostate cancer (mCRPC), non-metastatic castration-resistant prostate cancer …
-
European Commission Approves Astellas' Xtandi For Recurrent Early Prostate Cancer Treatment
24 Apr 2024 01:15 GMT
… recurrent non-metastatic hormone-sensitive prostate cancer who are unsuitable for salvage … the first and only novel hormone therapy available for the treatment of … with non-metastatic castration-sensitive prostate cancer with biochemical recurrent at high …
-
Preclinical efficacy of a PSMA-targeted actinium-225 conjugate (225Ac-macropa-pelgifatamab) - a targeted alpha therapy for prostate cancer.
23 Apr 2024 11:53 GMT
Initially, prostate cancer responds to hormone therapy but eventually … of metastatic castration-resistant prostate cancer. Here we introduce … - and patient-derived prostate cancer xenograft models. The … pelgi in patients with prostate cancer. A clinical phase …
-
Real-World Overall Survival and Treatment Patterns by PTEN Status in Metastatic Castration-Resistant Prostate Cancer.
22 Apr 2024 10:29 GMT
… patients with metastatic castration-resistant prostate cancer (mCRPC). There is limited … a deidentified US-based metastatic prostate cancer clinicogenomic database linked to … patients who received 1L novel hormone therapy or taxanes.
In patients with …
-
Black men and prostate cancer: OJ’s death reminds us to seek help early
19 Apr 2024 14:52 GMT
… likely to develop prostate cancer, and aggressive forms of prostate cancer, than any … to die from prostate cancer too.
What causes prostate cancer? Researchers don’t … cells; hormone therapy to suppress testosterone to lower the growth of prostate cancer.
Of …